Zhejiang Orient Gene Biotech's (SHA:688298) subsidiaries received medical device registration certificates for three detection kits, according to a Shanghai Stock Exchange disclosure on Wednesday.

The devices are hepatitis B virus nucleic acid detection kit (fluorescence PCR method), and pepsinogen I and II detection kits (time-resolved fluorescence immunochromatography).

The certificate for hepatitis B kit is valid until Dec. 29, 2029, while those for the pepsinogen kits are valid until Dec. 23, 2029, the disclosure added.

Shares of the company closed over 3% lower.